Respiratory infections in immunocompromised patients

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 3, 2009, Pages 209-217

  Corti, Marcelo ^a   Palmero, Domingo ^a   Eiguchi, Kumiko ^b  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b HOSPITAL DURAND   (Argentina)

Author keywords

AIDS; Cancer; Corticosteroid therapy; Immunosuppression; Pulmonary infections; Transplant recipients

Indexed keywords

ACICLOVIR; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BENZIMIDAVIR; CARBAPENEM; CEFTRIAXONE; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ETHAMBUTOL; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; ISONIAZID; ITRACONAZOLE; IVERMECTIN; LINEZOLID; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIABENDAZOLE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VANCOMYCIN; VORICONAZOLE; IMMUNOSUPPRESSIVE AGENT;

ACINETOBACTER; ADAPTIVE IMMUNITY; ANTIBIOTIC PROPHYLAXIS; BACTERIAL PNEUMONIA; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; ENTEROBACTER; ESCHERICHIA COLI; GRAFT RECIPIENT; HAEMOPHILUS INFLUENZAE; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; KLEBSIELLA; LEGIONNAIRE DISEASE; LOEFFLER PNEUMONIA; LUNG ASPERGILLOSIS; LUNG MYCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIOSIS; NOCARDIOSIS; PNEUMOCYSTOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; RHODOCOCCUS EQUI; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TUBERCULOSIS; VIRAL RESPIRATORY TRACT INFECTION; ZOONOSIS; IMMUNE DEFICIENCY; OPPORTUNISTIC INFECTION; PROGNOSIS; RESPIRATORY TRACT INFECTION; RISK FACTOR;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 67649222046     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328329bd2c     Document Type: Review

References (108)

1. Abbas AK, Lichtman AH, Pallai S. Innate immunity. In: Cellular and molecular immunology. 6th ed. London: Elsevier Science; 2007. pp. 19-46.
2. Randhawa AK, Hawn TR. Toll-like receptors: their roles in bacterial recognition and respiratory infections. Expert Rev Anti Infect Ther 2008; 6:479-495.
3. Slevogt H, Zabel S, Opitz B, et al. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat Immunol 2008; 9:1270-1278.
4. Pancer Z, Cooper MD. The evolution of adaptive immunity. Annu Rev Immunol 2006; 24:497-518.
5. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cell (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148:32-46.
6. Kaiko GE, Horvat JC, Beagley KW, Hasnbro PM. Immunological decisionmaking: how does the immune system decide to mount a helper T-cell response? Immunology 2007; 123:326-338.
7. Milner JD, Brenchley JM, Laurence A, et al. Impaired T (H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.
9. Franquet T. Respiratory infection in the AIDS and immunocompromised patient. Eur Radiol 2004; 14 (Suppl 3):E21-E33.
10. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008:CD006216.
11. Hashimoto M, Sugawara Y, Tamura S, et al. Methicillin-resistant Staphylococcus aureus infection after living-donor liver transplantation in adults. Transpl Infect Dis 2008; 10:110-116.
12. Shorr AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non- HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004; 125:260-271.
13. Levine DP. Vancomycin: understanding its past and preserving its future. South Med J 2008; 101:284-291.
14. Isakow W, Kollef MH. Preventing ventilator-associated pneumonia: an evidence- based approach of modifiable risk factors. Semin Respir Crit Care Med 2006; 7:5-17.
15. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings. Am J Infect Control 2007; 35 (10 Suppl 2): S165-S193.
16. Knirsch CA, Jakon K, Schoonmaker MS, et al. An outbreak of Legionella pneumonia in transplant patients: evaluation, molecular epidemiology, and control. Am J Med 2000; 108:290-295.
17. Gudiol C, Garcia-Vidal C, Fernández-Sabé N. Clinical features and outcomes of Legionnaires' disease in solid organ transplant recipients. Transpl Infect Dis 2008; 11:78-82.
18. Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP. Legionella pneumonia in cancer patients. Medicine (Baltimore) 2008; 87:152-159.
19. Falcó V, Molina I, Juste C, et al. Treatment for Legionnaires' disease. Macrolides or quinolones? Enferm Infecc Microbiol Clin 2006; 24:360-364.
20. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307-1314.
21. Poonyagariyagorn HK, Gershman A, Avery R, et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl Infect Dis 2008; 10:403-408.
22. Mart?́nez R, Reyes S, Menéndez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr Opin Pulm Med 2008; 14:219-227.
23. Yildiz O, Doganay M. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med 2006; 12:228-234.
24. Cronin SM, Abidi MH, Shearer CJ, et al. Rhodococcus equi lung infection in an allogeneic hematopoietic stem cell transplant recipient. Transpl Infect Dis 2008; 10:48-51.
25. Meeuse JJ, Sprenger HG, van Assen S, et al. Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia. Emerg Infect Dis 2007; 13:1942-1943.
26. Muñ oz P, Palomo J, Guinea J, et al. Relapsing Rhodococcus equi infection in a heart transplant recipient successfully treated with long-term linezolid. Diagn Microbiol Infect Dis 2008; 60:197-199.
27. Speck D, Koneth I, Diethelm M, Binet I. A pulmonary mass caused by Rhodococcus equi infection in a renal transplant recipient. Nat Clin Pract Nephrol 2008; 4:398-403.
28. Palmero D. Tuberculosis and HIV/AIDS. In: Palomino JC, Leao S, Ritacco V, editors. Tuberculosis 2007. From basic science to patient care. Berlin: Bourcilllier-Kamps; 2007. www.tuberculosistextbook.com.
29. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.
30. Shima T, Yoshimoto G, Miyamoto T, et al. Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia. Transpl Infect Dis 2008; 11:75-77. doi: 10.1111/j.1399- 3062.2008.00354.x.
31. Lionnet F, Bachmeyer C, Sloma I, et al. Tuberculosis in adult patients with sickle cell disease. J Infect 2007; 55:439-444.
32. Chou NK, Wang JL, Chi NH, et al. Tuberculosis after heart transplantation: twenty years of experience in a single center in Taiwan. Transplant Proc 2008; 40:2631-2633.
33. Boedefeld RL, Eby J, Boedefeld WM 2nd, et al. Fatal Mycobacterium tuberculosis infection in a lung transplant recipient. J Heart Lung Transplant 2008; 27:1176-1178.
34. Lindemann M, Dioury Y, Beckebaum S, et al. Diagnosis of tuberculosis infection in patients awaiting liver transplantation. Hum Immunol 2009; 70:24-28. doi: 10.1016/j.humimm.2008.10.005.
35. Morales P, Briones A, Torres JJ, et al. Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain. Transplant Proc 2005; 37:4050-4055.
36. Diel R, Loddenkemper R, Meywald-Walter K, et al. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot TB test in contact investigations for tuberculosis. Chest 2008. doi: 10.1378/ chest.08-2048. [Epub ahead of print]
37. Crump JA, Reller LB. Two decades of disseminated tuberculosis at a University Medical Center: the expanding role of mycobacterial blood culture. Clin Infect Dis 2003; 37:1037-1043.
38. Martin A, von Groll A, Fissette K, et al. Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual Mycobacterium Growth Indicator Tube System. J Clin Microbiol 2008; 46:3952-3956.
39. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Resp J 2005; 26:339-350.
40. Espinal M, Raviglione MC. From threat to reality: the real face of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2008; 178:216-217.
41. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis; 2008. WHO/HTM/TB/2008.402. International and up-dated guidelines about treatment of drug-resistant TB.
42. Corti M, Palmero D. Mycobacterium avium complex infection in HIV/AIDS patients. Expert Rev Anti Infect Ther 2008; 6:351-363.
43. Bishburg E, Zucker MJ, Baran DA, Arroyo LH. Mycobacterium xenopi infection after heart transplantation: an unreported pathogen. Transplant Proc 2004; 36:2834-2836.
44. Gaviria JM, Garcia PJ, Garrido SM, et al. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6:361-369.
45. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428-1439.
46. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
47. Johnson MM, Waller EA, Leventhal JP. Nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med 2008; 14:203-210.
48. Solari R, Corti M, Cangelosi D, et al. Disseminated histoplasmosis with lesions restricted to the larynx in a patient with AIDS. Report of a case and review of the literature. Rev Arg Micol 2007; 24:164-166.
49. Benetucci JA, Corti ME. Tratamiento de las infecciones endé micas de Latinoamé rica en pacientes VIH positivos. In: Gatell JM, Clotet B, Podzamczer D, Miró JM, Mallotas J, editors. Gu?́a Prá ctica del SIDA. 8th ed. Cl?́nica, Diagnó stico y Tratamiento. Barcelona (Españ a). Masson, S.A.; 2005. pp. 318-323.
50. Hage CA, Wheat LJ, Loyd J, et al. Pulmonary histoplasmosis. Semin Respir Crit Care Med 2008; 29:151-165.
51. Kauffman CA. Pulmonary histoplasmosis. Curr Infect Dis Rep 2001; 3:279-285.
52. Lacombe C, Lewin M, Monnier-Cholley L, et al. Imaging of thoracic pathology in patients with AIDS. J Radiol 2007; 88:1145-1154.
53. Corti M, Cendoya C, Soto I, et al. Disseminated histoplasmosis and AIDS: clinical aspects and diagnostic methods for early detection. AIDS Patient Care STDs 2000; 14:149-154.
54. Corti M, Negroni R, Esquivel P, Villafañe MF. Disseminated histoplasmosis in AIDS patients: epidemiological, clinical, microbiological and immunological analysis of 26 patients. Enf Emerg 2004; 6:8-15.
55. Hernández-Ros MR, Navarro-Ló pez V, Ruiz-Maciá JA, Corti M. A 34-year-old man with diarrhea and epigastralgia. Enf Infec Microbiol Clin 2008; 26:117-118.
56. Saccente M, McDonnell RW, Baddour LM, et al. Cerebral histoplasmosis in the azole era: report of four cases and review. South Med J 2003; 96:410-416.
57. Bianchi M, Robles AM, Vitale R, et al. The usefulness of blood culture systems in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis centrifugation method. Med Mycol 2000; 38:77-80.
58. Allton DR, Rivard RG, Connoly PA, et al. Antigen detection of Latin America strains of Histoplasma in a murine model. In: Abstract of 2007 Conference of the Infectious Disease Society of America; abstract 159.
59. Bialek R, Feucht A, Aepinus C, et al. Evaluation of two nested PCR assays for detection of Histoplasma capsulatum DNA in human tissue. J Clin Microbiol 2002; 40:1644-1647.
60. Gutierrez ME, Canton A, Connoly P, et al. Detection of Histoplasma capsulatum antigen in Panamanian patients with disseminated histoplasmosis and AIDS. Clin Vacc Immunol 2008; 4:681-683.
61. Keath EJ, Kobayashi GS, Medoff G. Typing of Histoplasma capsulatum by restriction fragment length polymorphisms in a nuclear gene. J Clin Microbiol 1992; 30:2104-2107.
62. Negroni R, Helou S, Ló pez Daneri G, et al. Discontinuation of antifungal secondary prophylaxis in AIDS-associated histoplasmosis. Rev Iberoam Micol 2004; 21:75-78.
63. Wheat JL, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807-825.
64. Schineider Casotti JA, Queiroz Reuter Motta T, Gonçalves Ferreira CU Jr, Cerrutti C Jr. Disseminated histoplasmosis in HIV positive patients in Espírito Santo State, Brazil: a clinical-laboratory study of 12 cases (1999-2001). Braz J Infect Dis 2006; 10:327-330.
65. White D, Zaman MK. Pulmonary disease. Med Clin North Am 1992; 76:19-40.
66. WuTT, Wang HC, Yang PC, et al. Pulmonary cryptococcosis: manifestations in the era of acquired immunodeficiency syndrome. J Formos Med Assoc 1999; 98:621-626.
67. Fang CT, Hung CC, Chang SC, et al. Pulmonary infection in human immunodeficiency virus-infected patients in Taiwan. J Formos Med Assoc 2000; 99:123-127.
68. Franquet T, Gimé nez A, Hidalgo A. Imaging of opportunistic fungal infections in immunocompromised patient. Eur J Radiol 2004; 51:130-138.
69. Corti M, Trione N, Semorile K, et al. Pulmonary cryptococcosis presenting as cavitated pneumonia in a patient with AIDS. Rev Iberoam Micol 2008; 25:65-68.
70. Castañ er E, Gallardo X, Mata JM, Esteba L. Radiologic approach to the diagnosis of infectious diseases in patients infected with the human immunodeficiency virus. Eur J Radiol 2004; 51:114-129.
71. Mulanovich VE, Dismukes WE, Markowitz N. Cryptococcal empyema: case report and review. Clin Infect Dis 1995; 20:1396-1398.
72. Rozenbaum R, Ríos Gonçalves AJ. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994; 18:369-380.
73. Huang L. Pulmonary infections in the immunocompromised host. http:// pats.atsjournals.org/cgi/content/full/5/7/755.
74. Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004; 128:1023-1027.
75. Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adults patients with AIDS. Treat Respir Med 2004; 3:381-397.
76. Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jiroveci pneumonia over the course of the AIDS epidemic. Clin Infect Dis 2008; 46:634-636.
77. Hidalgo A. Radiology of invasive fungal infections of the respiratory tract. Rev Iberoam Micol 2007; 24:14-18.
78. Villafañe MF, Corti M, Palmieri O, Trione N. Pneumocystis jirovecii (carinii) pneumonia undergoing cavitation. Medicina (Buenos Aires) 2004; 64:344.
79. Bollee G, Sarfati C, Thiery G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007; 132:1305-1310.
80. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004; 189:1679-1683.
81. Skelly M, Hoffman J, Fabbri M, et al. S-Adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 2003; 361:1267-1268.
82. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:693-699.
83. Dworkin MS, Williamson J, Jones JL, et al. Prophylaxis with trimethoprimsulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis 2001; 33:393-398.
84. Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46:625-633.
85. Utili R, Durante-Mangoni E, Basílico C, et al. Efficacy of capsofungin addition to trimethropim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 2007; 84:685-688.
86. Muñ oz P, Guinea J, Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006; 12 (Suppl 7):24-39.
87. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS. Review of 342 cases. Chest 1998; 114:251-262.
88. Park YS, Seo JB, Lee YK, et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol 2008; 63:673-680.
89. Marchiori E, Muller NL, Soares Souza A Jr, et al. Pulmonary disease in patients with AIDS: high-resolution CT and pathologic findings. AJR Am J Roentgenol 2005; 184:757-764.
90. Hao L, Jing CH, Bowen C, et al. Aspergillus sellar abscess: case report and review of the literature. Neurol India 2008; 56:186-188. A very interesting clinical case.
91. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40 (Suppl 6):S392-S400.
92. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008; 46:97-112.
93. Fardet L, Géné rau T, Cabane J, Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect 2006; 12:945-947.
94. Hsu YH. Disseminated strongyloidiasis. Tzu Chi Med J 2008; 20:76.
95. Sathe PA, Madiwale CV. Strongyloidiasis hyperinfection in a patient with membranoproliferative glomerulonephritis. J Postgrad Med 2006; 52:221-222.
96. Chan JFW, Choy BY, Lai KN. Nephrotic syndrome secondary to strongyloidiasis: a common infection with uncommon presentation. Hong Kong J Nephrol 2008; 10:37-41.
97. Roman Sánchez P, Pastor Guzman A, Moreno Guillen S, et al. Endemic strongyloidiasis on the Spanish Mediterranean coast. Q J Med 2001; 94:357-363.
98. Goyal SB. Intestinal strongyloidiasis manifesting as eosinophilic pleural effusion. South Med J 1998; 91:768-769.
99. Rivasi F, Pampiglione S, Boldorini R, Cardinale L. Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects. Arch Pathol Lab Med 2006; 130:1792-1798.
100. Pinheiro Veloso MG, Sperandio Porto A, Moraes M. Strongyloides stercoralis hyperinfection: autopsy case report. Rev Soc Bras Med Trop 2008; 41:413-415.
101. Streblow DN, Dumortier J, Moses AV, et al. Mechanisms of cytomegalovirusaccelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008; 325:397-415.
102. Torres HA, Aguilera E, Safdar A, et al. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect 2008; 14:1160-1166. doi: 10.1111/j.1469- 0691.2008.02106.x.
103. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008:CD003774. doi: 10.1002/14651858. CD003774.pub3.
104. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831-839.
105. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008:CD00650.
106. Boutolleau D, Deback C, Bressollette-Bodin C, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81:174-179. doi: 10.1016/j.antiviral.2008.11.003.
107. Trofe J, Pote L, Wade E, et al. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother 2008; 42:1447-1457.
108. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18:233-246.